Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Not Recruiting

Trial ID: NCT01011478


RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery. PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.

Official Title

Statin Polyp Prevention Trial in Patients With Resected Colon Cancer

Stanford Investigator(s)

Irene Wapnir, MD
Irene Wapnir, MD

Professor of Surgery (General Surgery)

Uri Ladabaum
Uri Ladabaum

Professor of Medicine (Gastroenterology and Hepatology)

Andrew A. Shelton, MD, FACS, FACRS
Andrew A. Shelton, MD, FACS, FACRS

Clinical Professor, Surgery - General Surgery


Inclusion Criteria

   - Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
   0 or 1.

   - Patients must have the ability to swallow oral medication.

   - Patients must have resected adenocarcinoma of the colon staged as American Joint
   Committee on Cancer (AJCC) Stage 0, I, II, or III.

   - Patients must have had surgical resection of the colon adenocarcinoma with curative
   intent within 1 year prior to randomization. (Laparoscopically-assisted colectomy is

   - Patients must have completed any adjuvant therapy prior to randomization.

   - Patients who are taking cardioprotective low-dose aspirin at study entry must not have
   clinically significant toxicity, as determined by the investigator, that precludes
   continuation of aspirin, and the patient must be willing to continue aspirin therapy
   (81 mg or 325 mg) throughout study therapy.

   - Colonoscopy requirements within 180 days prior to randomization:

   - The patient must have either undergone a preoperative or postoperative documented
   colonoscopy to the cecum (or small bowel anastomosis) with adequate bowel preparation.

   - All observed polyps must have been removed. (Polyps can be removed during colonoscopy
   or surgery performed prior to randomization.)

   - Postoperative serum creatinine performed within 90 days prior to randomization must be
   less than or equal to 1.5 x upper limit of normal (ULN) for the lab.

   - The following criteria for evidence of adequate hepatic function based on
   postoperative testing performed within 90 days prior to randomization must be met:
   aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than or equal
   to 3.0 x ULN for the lab, and Total bilirubin less than or equal to 1.5 x ULN for the

Exclusion Criteria

   - Tumor with the distal border located less than 12 cm from the anal verge.

   - Total colectomy or total proctocolectomy.

   - Classic Familial Adenomatous Polyposis, Attenuated Familial Adenomatous Polyposis
   (i.e., 20 or more adenomas, either synchronous or metachronous), or Hereditary
   Nonpolyposis Colorectal Cancer (Lynch Syndrome).

   - Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of
   the stomach or small bowel, or other disease significantly affecting gastrointestinal

   - History of documented upper GI bleeding or upper GI ulcerative disease.

   - Statin use within 30 days prior to randomization.

   - Hyperlipidemia with clinical indication for statin therapy or other prescribed
   medication. Determination of acceptable fasting lipid values, within 90 days prior to
   randomization, should be in accordance with current dyslipidemia management

   - Unwillingness to discontinue chronic use of nonsteroidal antiinflammatory drugs
   (NSAIDs) (other than cardioprotective low-dose aspirin 81 mg or 325 mg) prior to

   - Anticipated need for chronic use of NSAIDs (other than cardioprotective low-dose
   aspirin 81 mg or 325 mg).

   - Inadequately treated hypothyroidism, as determined by the investigator.

   - History of myopathy or rhabdomyolysis.

   - Hypersensitivity or intolerance to statins.

   - Chronic drug therapy with cyclosporine, coumarin anticoagulants, gemfibrozil, some
   other lipid-lowering therapies (fibrates or niacin), lopinavir/ritonavir, or drugs
   (such as ketoconazole, spironolactone, or cimetidine) that lower levels or activity of
   steroid hormones.

   - Pregnancy or lactation at the time of study entry. (Pregnancy testing must be
   performed within 14 days prior to randomization according to institutional standards
   for women of childbearing potential.)

   - Previous malignancies unless the patient has been disease-free for 5 or more years
   prior to randomization and is deemed by the physician to be at low risk for
   recurrence. Patients with the following cancers are eligible if diagnosed and treated
   within the past 5 years: all in situ cancers and basal cell and squamous cell
   carcinoma of the skin.

   - Other non-malignant systemic disease that would preclude a patient from receiving
   rosuvastatin or would prevent prolonged follow-up.

   - Administration of any investigational agent within 30 days before randomization.


drug: rosuvastatin

other: placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts